Prognostic Molecular Markers in Resected Extrahepatic Biliary Tract Cancers; A Systematic Review and Meta-Analysis of Immunohistochemically Detected Biomarkers

References

• Valle J , WasanH, PalmerDHet al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl J. Med.362(14), 1273–1281 (2010).
   PubMed Web of Science ®Google Scholar
• Patel T . New insights into the molecular pathogenesis of intrahepatic cholangiocarcinoma. J. Gastroenterol.49(2), 165–172 (2014).
   PubMed Web of Science ®Google Scholar
• Patel T . Worldwide trends in mortality from biliary tract malignancies. BMC Cancer2, 10 (2002).
   PubMed Web of Science ®Google Scholar
• DeOliveira ML , CunninghamSC, CameronJLet al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann. Surg.245(5), 755–762 (2007).
   PubMed Web of Science ®Google Scholar
• Ikeyama T , NaginoM, OdaKet al. Surgical approach to bismuth type I and II hilar cholangiocarcinomas: audit of 54 consecutive cases. Ann. Surg.246(6), 1052–1057 (2007).
   PubMed Web of Science ®Google Scholar
• Sirica AE . Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology41(1), 5–15 (2007).
   Web of Science ®Google Scholar
• Jarnagin WR , FongY, DeMatteoRPet al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann. Surg.234(4), 507–517; discussion 517–519 (2001).
   PubMed Web of Science ®Google Scholar
• Ruys AT , BuschOR, RauwsEAet al. Prognostic impact of preoperative imaging parameters on resectability of hilar cholangiocarcinoma. HPB Surgery (2013). http://dx.doi.org/10.1155/2013/657309.
   PubMedGoogle Scholar
• Briggs CD , NealCP, MannCDet al. Prognostic molecular markers in cholangiocarcinoma: a systematic review. Eur. J Cancer45(1), 33–47 (2009).
   PubMed Web of Science ®Google Scholar
• Moher D , LiberatiA, Tetzlaffet al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int. J. Surg.8(5), 336–341 (2010).
   PubMed Web of Science ®Google Scholar
• Smith RA , TangJ, Tudur-SmithCet al. Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. Br. J. Cancer104(9), 1440–1451 (2011).
   PubMed Web of Science ®Google Scholar
• Tierney JF , StewartLA, GhersiDet al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials8(16), doi:10.1186/1745-6215-6218-6216 (2007) ( Epub ahead of print).
   PubMedGoogle Scholar
• Williamson PR , SmithCT, HuttonJLet al. Aggregate data meta-analysis with time-to-event outcomes. Stat. Med.21(22), 3337–3351 (2002).
   PubMed Web of Science ®Google Scholar
• Parmar MK , TorriV, StewartLet al. Extracting summary statistics to perform meta-analyses of the published literature for survival end points. Stat. Med.17(24), 2815–2834 (1998).
   PubMed Web of Science ®Google Scholar
• Higgins JPT , ThompsonSG. Quantifying heterogeneity in a meta-analysis. Stat. Med.21(11), 1539–1558 (2002).
   PubMed Web of Science ®Google Scholar
• Sterne JAC , SuttonAJ, IoannidisJPAet al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ (2011). http://dx.doi.org/10.1136/bmj.d4002.
   PubMedGoogle Scholar
• Vousden KH , PrivesC. Blinded by the light: the growing complexity of p53. Cell137(3), 413–431 (2009).
   PubMed Web of Science ®Google Scholar
• Argani P , ShaukatA, KaushalMet al. Differing rates of loss of DPC4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts. Cancer91(7), 1332–1341 (2001).
   PubMed Web of Science ®Google Scholar
• Ellis LM . Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Semin. Oncol.33(5 Suppl. 10), S1–S7 (2006).
   PubMed Web of Science ®Google Scholar
• Batmunkh E , ShimadaM, MorineYet al. Expression of hypoxia-inducible factor-1 alpha [hif-1alpha] in patients with the gallbladder carcinoma. Int. J. Clin. Oncol.15(1), 59–64 (2010).
   PubMed Web of Science ®Google Scholar
• Hida Y , MoritaT, FujitaMet al. Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas. Anticancer Res.19(3B), 2257–2260 (1999).
   PubMed Web of Science ®Google Scholar
• Liu Y-F , ZhaoR, GuoSet al. Expression and clinical significance of hepatoma-derived growth factor as a prognostic factor in human hilar cholangiocarcinoma. Ann. Surg. Oncol.18(3), 872–879 (2011).
   PubMed Web of Science ®Google Scholar
• Okita S , KondohS, ShiraishiKet al. Expression of vascular endothelial growth factor correlates with tumor progression in gallbladder cancer. Int. J. Oncol.12(5), 1013–1018 (1998).
   PubMed Web of Science ®Google Scholar
• Nakashima T , KondohS, KitohHet al. Vascular endothelial growth factor-c expression in human gallbladder cancer and its relationship to lymph node metastasis. Int. J. Mol. Med.11(1), 33–39 (2003).
   PubMed Web of Science ®Google Scholar
• Greenhough A , SmarttHJM, MooreAEet al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis30(3), 377–386 (2009).
   PubMed Web of Science ®Google Scholar
• Brown JR , DuBoisRN. COX-2: a molecular target for colorectal cancer prevention. J. Clin. Oncol.23(12), 2840–2855 (2005).
   PubMed Web of Science ®Google Scholar
• Ishimura N , BronkSF, GoresGJ. Inducible nitric oxide synthase upregulates cyclooxygenase-2 in mouse cholangiocytes promoting cell growth. Am. J. Physiol. Gastrointest. Liver Physiol.287(1), G88–G95 (2004).
   PubMed Web of Science ®Google Scholar
• Isselbacher KJ . Sugar and amino acid transport by cells in culture – differences between normal and malignant cells. N. Engl. J. Med.286(17), 929–933 (1972).
   PubMed Web of Science ®Google Scholar
• Sung J-Y , KimGY, LimS-Jet al. Expression of the GLUT1 glucose transporter and p53 in carcinomas of the pancreatobiliary tract. Pathol. Res. Pract.206(1), 24–29 (2010).
   PubMed Web of Science ®Google Scholar
• Sharma PS , SharmaR, TyagiR. Inhibitors of cyclin dependent kinases: useful targets for cancer treatment. Curr. Cancer Drug Targets8(1), 53–75 (2008).
   PubMed Web of Science ®Google Scholar
• Cánepa ET , ScassaME, CerutiJMet al. INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions. IUBMB Life59(7), 419–426 (2007).
   PubMed Web of Science ®Google Scholar
• Polyak K , LeeMH, Erdjument-BromageHet al. Cloning of p27kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell78(1), 59–66 (1994).
   PubMed Web of Science ®Google Scholar
• Brembeck FH , RosárioM, BirchmeierW. Balancing cell adhesion and wnt signaling, the key role of beta-catenin. Curr. Opin. Genet. Dev.16(1), 51–59 (2006).
   PubMed Web of Science ®Google Scholar
• Noordermeer J , KlingensmithJ, PerrimonNet al. Dishevelled and armadillo act in the wingless signalling pathway in Drosophila. Nature367(6458), 80–83 (1994).
   PubMed Web of Science ®Google Scholar
• Tian X , LiuZ, NiuB, ZhangJet al. E-cadherin/β-catenin complex and the epithelial barrier. J. Biomed. Biotechnol. doi:10.1155/2011/567305 (2011) ( Epub ahead of print).
   Google Scholar
• Forbes SA , BindalN, BamfordSet al. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res.39(Database issue), D945–D950 (2010).
   PubMedGoogle Scholar
• Martinez-Rico C , PincetF, ThieryJ-Pet al. Integrins stimulate e-cadherin-mediated intercellular adhesion by regulating src-kinase activation and actomyosin contractility. J. Cell. Sci.123(Pt 5), 712–722 (2005).
   Google Scholar
• Wijnhoven BP , DinjensWN, PignatelliM. E-cadherin-catenin cell-cell adhesion complex and human cancer. Br. J. Surg.87(8), 992–1005 (2000).
   PubMed Web of Science ®Google Scholar
• Tao YS , EdwardsRA, TubbBet al. Beta-catenin associates with the actin-bundling protein fascin in a noncadherin complex. J. Cell. Biol.134(5), 1271–1281 (1996).
   PubMed Web of Science ®Google Scholar
• Vignjevic D , SchoumacherM, GavertNet al. Fascin, a novel target of beta-catenin-tcf signaling, is expressed at the invasive front of human colon cancer. Cancer Res.67(14), 6844–6853 (2007).
   PubMed Web of Science ®Google Scholar
• Onodera M , ZenY, HaradaKet al. Fascin is involved in tumor necrosis factor-alpha-dependent production of MMP9 in cholangiocarcinoma. Lab. Invest.89(11), 1261–1274 (2009).
   PubMed Web of Science ®Google Scholar
• Scholzen T , GerdesJ. The ki-67 protein: from the known and the unknown. J. Cell. Physiol.182(3), 311–322 (2000).
   PubMed Web of Science ®Google Scholar
• He X-R , WuX-P. Difference in biological characteristics and sensitivity to chemotherapy and radiotherapy between intrahepatic and extrahepatic cholangiocarcinoma cells in vitro. Chin. Med. Sci J.23(1), 54–59 (2008).
   PubMedGoogle Scholar
• Yang B , HouseMG, GuoMet al. Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma. Mod. Pathol.18(3), 412–420 (2005).
   PubMed Web of Science ®Google Scholar
• Easterbrook PJ , BerlinJA, GopalanRet al. Publication bias in clinical research. Lancet 337(8746), 867–872 (1991).
   Google Scholar
• Chang HJ , YooBC, KimSWet al. Significance of PML and p53 protein as molecular prognostic markers of gallbladder carcinomas. Pathol. Oncol. Res.13(4), 326–335 (2007).
   PubMed Web of Science ®Google Scholar
• Cheng Q , LuoX, ZhangBet al. Distal bile duct carcinoma: prognostic factors after curative surgery. A series of 112 cases. Ann. Surg. Oncol.14(3), 1212–1219 (2007).
   PubMed Web of Science ®Google Scholar
• Rijken AM , OfferhausGJ, PolakMMet al. P53 expression as a prognostic determinant in resected distal bile duct carcinoma. Eur. J. Surg. Oncol.25(3), 297–301 (1999).
   PubMedGoogle Scholar
• Suto T , SugaiT, NakamuraSet al. Assessment of the expression of p53, MIB-1 [ki-67 antigen], and argyrophilic nucleolar organizer regions in carcinoma of the extrahepatic bile duct. Cancer82(1), 86–95 (1998).
   PubMed Web of Science ®Google Scholar
• Takagawa M , MugurumaN, OguriKet al. Prediction of prognosis in gallbladder carcinoma by mucin and p53 immunohistochemistry. Dig. Dis. Sci.50(8), 1410–1413 (2005).
   PubMed Web of Science ®Google Scholar
• Won HS , LeeMA, ChungE-Set al. Comparison of thymidine phosphorylase expression and prognostic factors in gallbladder and bile duct cancer. BMC Cancer10, 564 (2010).
   PubMed Web of Science ®Google Scholar
• Kim YW , HuhSH, ParkYKet al. Expression of the c-erb-b2 and p53 protein in gallbladder carcinomas. Oncol. Rep.8(5), 1127–1132 (2001).
   PubMed Web of Science ®Google Scholar
• Do SI , KimGY, LimSJet al. Expression of cyclooxygenase-2 and embryonic lethal abnormal vision-like protein Hur in gallbladder carcinoma. Korean J. Pathol.44(1), 42–47 (2010).
   Google Scholar
• Kawamoto T , ShodaJ, AsanoTet al. Expression of cyclooxygenase-2 in the subserosal layer correlates with postsurgical prognosis of pathological tumor stage 2 carcinoma of the gallbladder. Int. J. Cancer98(3), 427–434 (2002).
   PubMed Web of Science ®Google Scholar
• Kim H , SongJ-Y, ChoJYet al. Strong cytoplasmic expression of COX2 at the invasive fronts of gallbladder cancer is associated with a poor prognosis. J. Clin. Pathol.63(12), 1048–1053 (2010).
   PubMed Web of Science ®Google Scholar
• Legan M , LuzarB, MaroltVF. Expression of cyclooxygenase-2, glucose transporter-1 and angiogenesis in gallbladder carcinomas and their impact on prognosis. Scand. J. Gastroenterol.44(9), 1101–1108 (2009).
   PubMed Web of Science ®Google Scholar
• Kim YW , ParkY-K, YoonTYet al. Expression of the GLUT1 glucose transporter in gallbladder carcinomas. Hepatogastroenterology49(46), 907–911 (2002).
   PubMedGoogle Scholar
• Hui AM , CuiX, MakuuchiM, LiXet al. Decreased p27[kip1] expression and cyclin D1 overexpression, alone and in combination, influence recurrence and survival of patients with resectable extrahepatic bile duct carcinoma. Hepatology30(5), 1167–1173 (1999).
   PubMed Web of Science ®Google Scholar
• Hui AM , LiX, ShiYZet al. Cyclin D1 overexpression is a critical event in gallbladder carcinogenesis and independently predicts decreased survival for patients with gallbladder carcinoma. Clin. Cancer Res.6(11), 4272–4277 (2000).
   PubMed Web of Science ®Google Scholar
• Zhao P , LuY, ZhongMet al. Inverse correlation of aberrant expression of fragile histidine triad [FHIT] protein with cyclin D1 protein and prognosis in Chinese patients with cholangiocarcinoma. Acta Oncol.47(8), 1557–1563 (2008).
   PubMed Web of Science ®Google Scholar
• Ichikawa K , ImuraJ, KawamataHet al. Down-regulated p16 expression predicts poor prognosis in patients with extrahepatic biliary tract carcinomas. Int. J. Oncol.20(3), 453–461 (2002).
   PubMed Web of Science ®Google Scholar
• Hong S-M , ChoiJ, RyuKet al. Promoter hypermethylation of the p16 gene and loss of its protein expression is correlated with tumor progression in extrahepatic bile duct carcinomas. Arch. Pathol. Lab. Med.130(1), 33–38 (2006).
   PubMed Web of Science ®Google Scholar
• Shi YZ , HuiAM, LiX, TakayamaTet al. Overexpression of retinoblastoma protein predicts decreased survival and correlates with loss of p16ink4 protein in gallbladder carcinomas. Clin. Cancer Res.6(10), 4096–4100 (2000).
   PubMed Web of Science ®Google Scholar
• Li H-W , YaoK, JinH-Yet al. Proteomic analysis of human lens epithelial cells exposed to microwaves. Jpn. J. Ophthalmol.51(6), 412–416 (2007).
   PubMed Web of Science ®Google Scholar
• Sanada T , YokoiS, AriiSet al. Skp2 overexpression is a p27kip1-independent predictor of poor prognosis in patients with biliary tract cancers. Cancer Sci.95(12), 969–976 (2004).
   PubMed Web of Science ®Google Scholar
• Tamada S , ShibaharaH, HigashiMet al. MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma. Clin. Cancer Res.12(14 Pt 1), 4257–4264 (2006).
   PubMed Web of Science ®Google Scholar
• Chang HJ , JeeCD, KimWH. Mutation and altered expression of beta-catenin during gallbladder carcinogenesis. Am. J. Surg. Pathol.26(6), 758–766 (2002).
   PubMed Web of Science ®Google Scholar
• Hirata K , AjikiT, OkazakiTet al. Frequent occurrence of abnormal e-cadherin/beta-catenin protein expression in advanced gallbladder cancers and its association with decreased apoptosis. Oncology71(1–2), 102–110 (2006).
   PubMed Web of Science ®Google Scholar
• Mikami T , SaegusaM, MitomiHet al. Significant correlations of e-cadherin, catenin, and CD44 variant form expression with carcinoma cell differentiation and prognosis of extrahepatic bile duct carcinomas. Am. J. Clin. Pathol.116(3), 369–376 (2001).
   PubMed Web of Science ®Google Scholar
• Ohashi M , KusumiT, SatoFet al. Expression of syndecan-1 and e-cadherin is inversely correlated with poor patient’s prognosis and recurrent status of extrahepatic bile duct carcinoma. Biomed. Res.30(2), 79–86 (2000).
   Google Scholar
• Roh YH , KimYH, ChoiHJet al. Fascin overexpression correlates with positive thrombospondin-1 and syndecan-1 expressions and a more aggressive clinical course in patients with gallbladder cancer. J. Hepatobiliary Pancreat. Surg.16(3), 315–321 (2009).
   PubMedGoogle Scholar
• Won KY , KimGY, LimS-Jet al. Prognostic significance of fascin expression in extrahepatic bile duct carcinomas. Pathol. Res. Pract.205(11), 742–748 (2009).
   PubMed Web of Science ®Google Scholar
• Hui A-M , ShiY-Z, LiXet al. Proliferative marker ki-67 in gallbladder carcinomas: high expression level predicts early recurrence after surgical resection. Cancer Lett.176(2), 191–198 (2002).
   PubMed Web of Science ®Google Scholar
• Li S-H , LiC-F, SungM-Tet al. Skp2 is an independent prognosticator of gallbladder carcinoma among p27[kip1]-interacting cell cycle regulators: an immunohistochemical study of 62 cases by tissue microarray. Mod. Pathol.20(4), 497–507 (2007).
   PubMed Web of Science ®Google Scholar
• Rijken AM , UmezawaA, van GulikTMet al. Prognostic value of cell proliferation [ki-67 antigen] and nuclear DNA content in clinically resectable, distal bile duct carcinoma. Ann. Surg. Oncol.5(8), 699–705 (1998).
   PubMed Web of Science ®Google Scholar